Botanical decision model to identify evidence thresholds suggested by OAM's Jonas.
This article was originally published in The Tan Sheet
Executive Summary
BOTANICAL CLINICAL EVALUATION MODEL TO ALLOW "INTERMEDIATE DECISIONS" on the usefulness of a substance was suggested by NIH Office of Complementary and Alternative Medicine Director Wayne Jonas, MD, at a Drug Information Association meeting in Washington, D.C. Jan. 28. Jonas discussed an approach for botanicals that he said "might allow us to break out of the rigid boundaries" of current clinical efficacy testing requirements and allow for a less expensive, less complicated testing program.